undamentalytics Newsletter

Catinazzo Thomas: insider trades

Chief financial officer, Officer at Relay Therapeutics, Inc. No open-market purchases and 17 sales not made under a pre-set plan, reported from June 30, 2021 to October 30, 2026.

What happened after Catinazzo Thomas’s sales?

After their sales, the shares moved −59.7% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Catinazzo Thomas: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 15 −3.7% −7.5% 53% 6 −0.17 0.87 No reliable evidence
Sales, 12 months after the report 11 −59.7% −55.0% 100% 4 −6.64 0.007 Some evidence: seller right
Sales, 12 months after the trade 12 −42.6% −53.2% 92% 5 −0.41 0.70 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Relay Therapeutics, Inc. RLAY Chief Financial Officer017June 30, 2021October 30, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
October 30, 2026October 28, 2026 RLAY Sale $27,353 not yetnot yetnot yet
July 30, 2026July 28, 2026 RLAY Sale $27,152 +0.2%not yetnot yet
April 30, 2026April 28, 2026 RLAY Sale $14,376 +42.2%not yetnot yet
January 29, 2026January 27, 2026 RLAY Sale $119,631 +61.6%not yetnot yet
October 30, 2025October 28, 2025 RLAY Sale $157,931 +20.0%not yet+145.7%
July 30, 2025July 28, 2025 RLAY Sale $74,000 not yetnot yetnot yet
April 29, 2024April 29, 2024 RLAY Sale $10,814 +16.0%−64.5%−61.0%
January 31, 2024January 29, 2024 RLAY Sale $19,328 −25.8%−73.8%−79.1%
November 1, 2023October 30, 2023 RLAY Sale $10,233 +2.6%−55.0%−49.8%
July 31, 2023July 28, 2023 RLAY Sale $19,977 −39.1%−53.5%−52.6%
January 31, 2023January 30, 2023 RLAY Sale $18,628 −48.0%−80.7%−78.2%
November 1, 2022October 28, 2022 RLAY Sale $23,672 −7.5%−82.7%−79.9%
September 29, 2022September 27, 2022 RLAY Sale $10,069 −40.8%−80.8%−84.4%
July 29, 2022July 28, 2022 RLAY Sale $15,605 +29.4%−48.1%−52.8%
May 2, 2022April 28, 2022 RLAY Sale $18,538 −23.3%−53.7%−53.6%
September 27, 2021September 27, 2021 RLAY Sale $10,803 −26.0%−21.4%−21.1%
June 30, 2021June 28, 2021 RLAY Sale $10,492 −17.0%−42.2%−44.8%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Catinazzo Thomas traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.